chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Symptoms - ?Patient reports immediately after injection really bad arm pain and described as ?nerve pain, stinging in nature.?  Patient verbalizing concerns with injection technique by vaccine administrator. Patient reports he didn?t think anything of it and worked night shift (7p-7a) on 1/10, 1/11, 1/12 without improvement. Patient reports he worked on 1/19, 1/20, 1/21 and Patient reports pain to R scapula. Patient reports he used Acetaminophen; Ibuprofen and muscle rub without relief.  Patient notified EH and had appointment with PA on 2/1. Patient reports he has been receiving PT at TCH twice/weekly. Patient reports he was prescribed Gabapentin and reports significant relief. Patient had f/u appointment today (2/11) with PA and was notified to contact us to report adverse reaction.  EE reports he was told by  PA to contact ?occupational health? for more assistance. Patient notified vaccine support line is for adverse reactions to vaccine and Patient verbalized he was unsure who he was supposed to contact. Patient notified to contact PA directly as he is under his care and ask for the contact phone number/email of who he needs to contact next.  patient reports next f/u appointment scheduled with EH on March 4th. Patient verbalized back understanding and denied further questions at this time. Last day of work and shift - unknown, Patient did not disclose. Home remedies? -   see ?symptoms? for detailed account Any improvement? - yes Recommendation?  Patient educated to continue to follow instructions provided by PA at EH as he is under his medical care.  Patienteducated to contact  PA at EH with further questions or concerns regarding management of care.
Fever (high 101.7), chills, sweating, fatigue, headache, stomachache, nausea, leg weakness. Started upon waking in the morning 06/05, resolved by the time he woke on 06/06. Took Tylenol for fever twice on 06/05.
At nite very ill, slept 17 hrs. Legs very weak, headaches, spasms, upper back two weeks of this could hardly make meals. I am still not better. I cant event go food shopping or clean house.
Swollen lymph gland under left arm on day 2. Began sometime in the night.
Morning after 1st vaccination dose experienced flu-like symptoms (aches, tired, light headed, chills). Took acetaminophen 3 times throughout day to alleviate symptoms. Symptoms cleared by 2nd morning.    Injection site soreness for ~3 days after injection.
nausea, dizziness, and headache; nausea, dizziness, and headache; nausea, dizziness, and headache; This is a spontaneous report from a contactable consumer (patient). This 56-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration, on an unspecified date, at single dose, for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient experienced nausea, dizziness, and headache. Clinical outcome of the events was unknown at time of this report.   Information on the Lot/batch number has been requested.
Developed a red itchy small circle (quarter size) at injection site about 4-5 hours after injection. Lasted day of and day after. It was gone on the third day.  A week and a day after injection the itchy red circle appeared in larger size and more defined circle. Disappeared the next day. On day 12 after injection the rash had expanded to almost half my arm. It was a bit itchy at times and this time it was not circular, instead irregular shape with defined square like borders on one end. It lasted 2 days, disappeared and hasn?t come back yet.
severe swelling from elbow to shoulder in arm where vax recv;area erythematous & hot to touch;swelling cont 2 days p/vax;pt saw own MD days p/vax given;
Patient presented to the ED vaccination clinic on 12/20.  She received her first dose of the vaccine, and then went into the breakroom to finish the rest of her lunch break.  Approximately 10 minutes after she received her vaccine, she noticed she was feeling very warm, like a hot flash.  She asked her coworker if it was hot in the breakroom, who responded no.  She then noticed that she was developing reds spots on her chest, back and neck.  We moved her into a private area to monitor her, and allow her to undress and cool off.  She developed redness to her chest, back, neck, and redness around the injection site.  This mostly resolved within 45 minutes.  At about 45 minutes, I was able to secure PO Benadryl and provided her 50 mg of Benadryl, which she took.  The employee returned to work the rest of her shift with no other complications noted.  The employee denied swelling or itching to the throat, denied SOB, and her vital signs were normal the entire time. The employee does want to get her 2nd dose of the vaccine, so we will plan on administering it in the ED, and may pre-medicate with Benadryl.
Loss of control of limbs, not able to sit or stand, talking irrationally, 105 temperature.
No reactions, no symptoms. Patient tolerated vaccine well but vaccine administered was expired by almost 3 months.
Patient developed petechiae within 24yhr, got worse over 48hrs and then stabilized.
Pt has advanced dementia and lives in an assisted living appt with her husband.   Pt has been exposed to COVID and has had worsening mental status.  Pt found to be COVID positive and admitted for acute sepsis.
Information has been received from a physician concerning a female who "about 3 weeks ago," on approximately 20-JUN-2008 was vaccinated with a dose of ZOSTAVAX. "2 weeks after the dose," on approximately 04-JUL-2008 the patient experienced shingles. The patient went to see a physician. At the time of report, the event's outcome was unknown. Additional information has been requested.
Client was administered her second dose of COVID-19 vaccine and immediately afterwards she stated her mouth was dry, her heart was racing, her throat felt dry and she found it difficult to breathe. She stated that she had the same symptoms after she received her first dose. 911 was immediately called. Her vital signs were as follows: BP=108/80, Pulse=88, Respiration=18. She denied any history of allergies but said she had asthma, for which she took Ventolin. She did not have any dizziness. The EMT personnel arrived shortly thereafter and determined she was having a panic attack. The client as well as the EMT did not think it was necessary to transport her to the hospital. They spoke with her until she felt calm and ready to leave the POD site. She was told to call 911 if the symptoms occurred again and she verbalized understanding.
Information has been received from a physician, via a company representative, concerning a female patient (age not specified) who in early November 2007 had started her period, and was then vaccinated with a dose of GARDASIL vaccine (yeast) (lot # not specified). The physician noted that the patient's period "suddenly stopped" after the vaccination. On approximately 26-NOV-2007 ("just started"), the patient's suddenly started again. The physician questioned if the event was related to GARDASIL vaccine (yeast). At the time of this report, the outcome of the event was unknown. Additional information has been requested.
first time ever got flu; Initial information was received on 20-Nov-2021 regarding an unsolicited valid, social media, non-serious case received from a Consumer.  This case involves a patient (unknown age and gender) who experienced first time ever got flu (influenza) while receiving INFLUENZA VACCINE.  Medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.  On an unknown date in 2009, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) [lot number not reported, and expiry date not provided] via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date in 2009, the patient experienced first time ever got flu (influenza) (unknown latency) following the administration of INFLUENZA VACCINE  It is unknown if the patient experienced any additional symptoms/events.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of report, the outcome of event was unknown.  There will be no information available on batch number for this case.
my uncle had a heart attack a week after getting the vaccine; This is a spontaneous report from a contactable consumer (patient's niece). A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Lot number and expiration date was not reported) as unknown, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The reporter stated that her uncle had a heart attack a week after getting the vaccine on an unspecified date with outcome of unknown.  Information on batch/lot number has been requested.
After receiving vaccine on 02/5/2021, I had a rash on back on left thigh felt like a sciatica pain along with fever chills. 6 days later after booster on 12/7/2022 I had the same reaction with the rash on the back on leg and severe pain and chills. I treat it with Valtrex and after about 11 days it went away.
Fever the following day along with hives and flushing blisters in mouth and throat two days after received vaccination. Patient went to Emergency Room and placed on oral steroids.
Patient states she developed a sore arm with swelling 1 day after the administration.  She has since developed an area of redness measuring 10.5 cm X 5.7 cm.  Redness is just below the injection site.  Redness is tender, without warmth or streaking.
This spontaneous report as received from a nurse refers to an 5 months 23 days old female patient. No concurrent condition, medical history or allergy/drug reactions were reported. On an unspecified date, the patient was vaccinated with improperly stored (exposed to 52.8 Fahrenheit for a total of 105 hours) ROTATEQ lot # K016313, exp. date: 31-MAY-2016 and lot # K011663, exp. date: 20-MAY-2016 (dose and strength unspecified) oral. No concomitant medications were reported. No adverse experiences have been reported so far. There were no product quality complaints (PQC) involved. No additional information was provided. This is one of several reports received from the same reporter. Additional information is not expected, no contact details were provided.
A couple of days after receiving the vaccine, the inside of my arm was itching and my face felt flushed. I went to urgent care and told them what was happening; the doctor there prescribed me a steroid prescription of Timolol and Decadron and Prednisone at-home prescription to take as well to help relieve the allergic reaction I was seeming to have to the vaccine. I've been better since the injections and will begin my Prednisone steroid prescription today.
J&J COVID-19 Vaccine  I received fever, chills, fatigue, headache 10 hours after getting the vaccine. My fever got as high as 101.5, but now is down to 99.9 (47 hours after vaccination). My fever has gone down due to taking Tylenol every four hours. Chills and headache have gone, but general fatigue is still present.
The text phone contacts to me have not worked for past two days. My symptoms now are fatigue, general achy joints and muscles, slight swelling and pain at the injection site.  I am fine but need help with the survey sent via text does not work.  Unable to "Do your weekly post-vaccination check in".
mod sized blisters cover mouth, inside under nose top lip 2 days p/flu vax very itchy-none on hands;
This spontaneous report was received from a pharmacist refers to an adult patient of unknown age and gender. On 29-JUN-2015, an adult patient was vaccinated in error with a dose of PEDVAXHIB (dose and lot# were not reported) intramuscular. No adverse effects reported. No Product quality Complaint (PQC) was involved. Additional information has been requested.
A non-serious, spontaneous report of tingling in upper extremities, flushing and dysphagia has been received from a physician on concerning a 33-year-old male patient subsequent to FLUMIST. The patient's medical history included exercises induced asthma. The patient was not receiving any concomitant medications. The patient received FLUMIST, intranasal on 05-Oct-2009. On 05-Oct-2009, immediately after receiving FLUMIST, the patient experienced tingling in both upper extremities, facial flushing and dysphagia. The patient was seen in the emergency department and was noted to have a normal exam. The patient was considered recovered from the events of tingling in upper extremities, flushing and dysphagia on 05-Oct-2009. On 06-Oct-2009 the patient was seen as an outpatient and was asymptomatic.
Felt full effect of COVID, same as day 1; asthma seemed to be worse; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Felt full effect of COVID, same as day 1) and ASTHMA (asthma seemed to be worse) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Asthma and Allergy (Drug name was not reported(past drug history)). Concomitant products included BUPROPION HYDROCHLORIDE (WELLBUTRIN) for an unknown indication.    On 04-Mar-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-May-2022, the patient experienced COVID-19 (Felt full effect of COVID, same as day 1) and ASTHMA (asthma seemed to be worse). At the time of the report, COVID-19 (Felt full effect of COVID, same as day 1) and ASTHMA (asthma seemed to be worse) had not resolved.            It was reported that patient previously received a COVID-19 vaccine. Patient was taking other medications or products within 2 weeks of starting COVID-19 treatment. Patient received covid-19 treatment from 05-May-2022 to 09-May-2022 with unknown Pfizer medication. Device date was reported as 17-May-2022.  Company Comment:  This spontaneous case concerns a 63-year-old female patient with concurrent Asthma, who experienced the unexpected non-serious adverse event of special interest COVID-19 (Felt full effect of COVID, same as day 1), that occurred 2 months and 11 days after receiving mRNA-1273 Vaccine as fourth dose in the COVID-19 vaccination series.  Patient underwent COVID-19 treatment for 5 days with an unspecified Pfizer product 10 days prior to the onset of the event.  Six days after completion of COVID-19 treatment, patient reportedly experienced the full effect of COVID-19 as when she had it on day 1 along with worsened asthma. No information was provided on the previous 3 doses of COVID-19 vaccines received by the patient. The concurrent asthma could be considered as a contributory factor to COVID-19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 63-year-old female patient with concurrent Asthma, who experienced the unexpected non-serious adverse event of special interest COVID-19 (Felt full effect of COVID, same as day 1), that occurred 2 months and 11 days after receiving mRNA-1273 Vaccine as fourth dose in the COVID-19 vaccination series.  Patient underwent COVID-19 treatment for 5 days with an unspecified Pfizer product 10 days prior to the onset of the event.  Six days after completion of COVID-19 treatment, patient reportedly experienced the full effect of COVID-19 as when she had it on day 1 along with worsened asthma. No information was provided on the previous 3 doses of COVID-19 vaccines received by the patient. The concurrent asthma could be considered as a contributory factor to COVID-19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
WET COUGH; RESPIRATORY INFLAMMATION; HEADACHE; FEVER; SORE THROAT; RUNNY NOSE; FEELING BAD; This spontaneous report received from a patient concerned a 64 year old male. The patient's weight was 225 pounds, and height was 73 inches. The patient's pre-existing medical conditions included the patient was prescribed an oral 7day unspecified steroid regimen for his respiratory inflammation, which he was still taking. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A, and batch number: 206A21A expiry: UNKNOWN) dose was not reported, administered on 03-MAY-2021 for prophylactic vaccination. No concomitant medications were reported.  On 17-JUN-2021, the subject experienced sore throat. On 17-JUN-2021, the subject experienced runny nose. On 17-JUN-2021, the subject experienced feeling bad. On 17-JUN-2021, the subject experienced headache. On 17-JUN-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99 F. On 19-JUN-2021, treatment medications included: azithromycin. On 22-JUN-2021, Laboratory data included: COVID-19 virus test (NR: not provided) Negative. On an unspecified date, the subject experienced wet cough, and respiratory inflammation. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from sore throat, runny nose, and headache, and fever on JUN-2021, had not recovered from wet cough, and the outcome of feeling bad and respiratory inflammation was not reported. This report was non-serious.
This spontaneous report as received from a nurse refers to unspecified patients of unknown age and gender. The patient's pertinent medical history, current conditions and concomitant medications were not reported. No previous drug reactions or allergies were reported. On the following below listed dates multiple unspecified patients were vaccinated with improperly stored M-M-R II lot # L015280 expiry date of 30-APR-2017 and L012481 expiry date 10-APR-2017. On 09-FEB-2016 and 13-FEB-2016 the M-M-R II, was exposed to a lowest temperature of +1.0 degree centigrade for 29 minutes and 30 minutes respectively. On 10-FEB-2016, 11-FEB-2016, 14-FEB-2016 and 16-FEB-2016, M-M-R II, was exposed to a lowest temperature of +1.2 degree centigrade for 25 minutes, 22 minutes, 24 minutes and 34 minutes respectively. On 12-FEB-2016, M-M-R II, was exposed temperature of +1.3 degree centigrade for 21 minutes. On 15-FEB-2016, M-M-R II, was exposed to a lowest temperature of +1.1 degree centigrade for 25 minutes. On 17-FEB-2016, M-M-R II, was exposed temperature of +0.0 degree centigrade duration not reported. On 18-FEB-2016 M-M-R II, was exposed to a lowest temperature of -1.0 degree centigrade for 12 hours 29 minutes. On 19-FEB-2016 M-M-R II, was exposed to a lowest temperature of -1.1 degree centigrade for 12 hours 1 minute. Also reported that the vaccine was administered on an unspecified date from 20-FEB-2016 to 29-FEB-2016. On an unknown date the patients were vaccinated with improperly stored M-M-R II, lot # L015460 with an expiry date of 20-JUL-2017. Dosing details were not provided. No adverse effects were reported. There was no product quality complaint involved. This is one of the several reports received from the same reporter. Additional information has been requested.
tested positive; tested positive; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 58-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 12Oct2021 as dose 3 (booster), single (Lot number: FD0810) at the age of 58 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Known Allergies: Penicillin" (unspecified if ongoing). Concomitant medication(s) included: ATORVASTATIN. Past drug history included: Known allergies: codeine for Known allergies: Codeine. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete but unknown manufacturer, Dose 1), for Covid-19 immunization; Covid-19 vaccine (Primary Immunization series complete but unknown manufacturer, Dose 2), for Covid-19 immunization.  The following information was reported: DRUG INEFFECTIVE (medically significant) with onset 13Apr2022, outcome "unknown", COVID-19 (medically significant) with onset 13Apr2022, outcome "recovered" (23Apr2022) and all described as "tested positive". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (29Mar2022) Negative; (13Apr2022) Negative; (13Apr2022) Positive; (23Apr2022) Negative. Therapeutic measures were not taken as a result of covid-19.  Clinical course: Began taking Paxlovid on 26Mar2022; took full course. Tested negative starting 29Mar. Continued to test negative until 13Apr2022. her husband became ill and tested positive on 12Apr2022. She became ill the next day and tested positive and self-isolated with cold-like symptoms - no fever, just nasal drip and cough. Symptoms resolved within 10 days. Tested negative 23Apr2022.
Very fatigued; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Very fatigued) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) and VITAMINS NOS for an unknown indication.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced FATIGUE (Very fatigued). The patient was treated with CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]) at an unspecified dose and frequency. At the time of the report, FATIGUE (Very fatigued) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
6 hours post vax, the pt developed severe localized reaction. Initially, painful abduction of left arm with gradually increasing erythema and induration at left deltoid measuring 70 mm x 60 mm.
Improper booster dose administered of 0.5 ml booster dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of ACCIDENTAL OVERDOSE (Improper booster dose administered of 0.5 ml booster dose) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 ml. On 19-Nov-2021, the patient experienced ACCIDENTAL OVERDOSE (Improper booster dose administered of 0.5 ml booster dose). On 19-Nov-2021, ACCIDENTAL OVERDOSE (Improper booster dose administered of 0.5 ml booster dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.
vaccinated on 1/21/2021 symptoms of one large hive at site on injection on 02/02/2021